Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: Intravascular ultrasonography analysis of the SOS (Stenting Of Saphenous Vein Grafts) trial

EuroIntervention

Volumn 7, Issue 8, 2011, Pages 948-954

  Jeroudi, Omar M ^a,b   Abdel Karim, Abdul Rahman R ^a,b   Michael, Tesfaldet T ^a,b   Lichtenwalter, Christopher ^a,b   De Lemos, James A ^a,b   Obel, Owen ^a,b   Addo, Tayo ^a,b   Roesle, Michele ^a   Haagen, Donald ^a   Rangan, Bavana V ^a   Raghunathan, Deepa ^a,b   DaSilva, Monica ^a,b   Saeed, Bilal ^c   Bissett, Joseph K ^d   Sachdeva, Rajesh ^d   Voudris, Vassilios V ^e   Karyofillis, Panagiotis ^e   Kar, Biswajit ^f   Rossen, James ^g   Fasseas, Panayotis ^h   Berger, Peter ⁱ   Banerjee, Subhash ^a,b   Brilakis, Emmanouil S ^a,b   more..

^a Veterans Affairs North Texas Health Care System   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e ONASSIS CARDIAC SURGERY CENTER   (Greece)

^f MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ GEISINGER MEDICAL CENTER   (United States)

Author keywords

Intravascular ultrasonography; Neointimal hyperplasia; Paclitaxel eluting stent; Saphenous vein graft

Indexed keywords

PACLITAXEL;

AGED; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DISEASE COURSE; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SAPHENOUS VEIN GRAFT;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG-ELUTING STENTS; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; NEOINTIMA; PACLITAXEL; SAPHENOUS VEIN; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84855395954     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV7I8A150     Document Type: Article

References (33)

1. Brilakis ES, Wang TY, Rao SV, Banerjee S, Dai D, Chin CT, Harding TM, Roe MT. Frequency and Predictors of Drug-Eluting Stent Use in Saphenous Vein Bypass Graft Percutaneous Coronary Interventions: A Report from the American College of Cardiology National Cardiovascular Data CathPCI Registry®. JACC Cardiovasc Interv. 2010;10:1068-73.
2. Brilakis ES, Saeed B, Banerjee S. Drug-eluting stents in saphenous vein graft interventions: a systematic review. EuroIntervention. 2010;5:722-30.
3. Lee MS, Yang T, Kandzari DE, Tobis JM, Liao H, Mahmud E. Comparison by meta-analysis of drug-eluting stents and bare metal stents for saphenous vein graft intervention. Am J Cardiol. 2010; 105:1076-82.
4. Meier P, Brilakis ES, Conti R, Knapp G, Shishehbor MH, Gurm HS. Drug-eluting versus bare-metal stent for treatment of saphenous vein grafts: a meta-analysis. Plos One. 2010;5:e11040.
5. Joyal D, Filion KB, Eisenberg MJ. Effectiveness and safety of drug-eluting stents in vein grafts: a meta-analysis. Am Heart J. 2010;159:159-69 e4.
6. Sanchez-Recalde A, Valero SJ, Moreno R, Barreales L, Lozano I, Galeote G, Reyes RM, Calvo L, Lopez-Sendon JL. Safety and efficacy of drug-eluting stents versus bare-metal stents in saphenous vein grafts lesions: a meta-analysis. EuroIntervention. 2010;6:149-60.
7. Testa L, Agostoni P, Vermeersch P, Biondi-Zoccai G, Van Gaal W, Bhindi R, Brilakis E, Latini RA, Laudisa ML, Pizzocri S, Lanotte S, Brambilla N, Banning A, Bedogni F. Drug eluting stent versus bare metal stent in the treatment of saphenous vein graft disease. A systematic review and meta-analysis. EuroIntervention. 2010;6:527-536.
8. Brilakis ES, Berger PB. Should Bare Metal or Drug-Eluting Stents Be Used During PCI of Saphenous Vein Graft Lesions: Waiting For Godot? Catheter Cardiovasc Interv. 2008;72:815-8.
9. Hakeem A, Helmy T, Munsif S, Bhatti S, Mazraeshahi R, Cilingiroglu M, Effat M, Leesar M, Arif I. Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: A comprehensive meta-analysis of randomized trials and observational studies comprising 7,994 patients. Catheter Cardiovasc Interv. 2010;published online before print.
10. Paradis J-M, Bélisle P, Joseph L, Bertrand OF, DeLarochellière R, Déry J-P, Larose E, Rodés-Cabau J, Rinfret S. Drug-Eluting or Bare Metal Stents for the Treatment of Saphenous Vein Graft Disease. Circ Cardiovasc Interv. 2010;3:565-76.
11. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol. 2009;53:919-28.
12. Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Holper EM, Haagen D, Saeed B, Iturbe JM, Shunk K, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. JACC Cardiovasc Interv. 2009;2:855-60.
13. Badhey N, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Addo TA, Haagen D, Abdel-Karim, A, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger PB, Banerjee S, Brilakis ES. Contemporary Use of Embolic Protection Devices in Saphenous Vein Graft Interventions: Insights from the SOS (Stenting Of Saphenous vein grafts) Trial. Catheter Cardiovasc Interv. 2010;76:263-9.
14. Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Roesle M, Obel OO, Addo TA, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger PB, Banerjee S. Continued Benefit from Paclitaxel-Eluting Compared to Bare Metal Stent Implantation in Saphenous Vein Graft Lesions During Long-Term Follow-Up of the SOS (Stenting Of Saphenous vein grafts) Trial. JACC Cardiovasc Interv. 2011:in press.
15. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, Guagliumi G, Wijns W, Lindeboom WK, Ligthart J, de Feyter PJ, Morice MC, RAVEL Study Group. Intravascular Ultrasound Findings in the Multicenter, Randomized, Double-Blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) Trial. Circulation. 2002;106:798-803.
16. Weissman NJ, Koglin J, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Kutcher M, Wong SC, Strickland W, Mooney M, Russell ME, Ellis SG, Stone GW. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: A serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1201-5. (Pubitemid 40523137)
17. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998;97:916-31. (Pubitemid 28113931)
18. Rittersma SZ, van der Wal AC, de Winter RJ. Eosinophilic tissue response several weeks after sirolimus-eluting cypher stent implantation within a bare metal stent in a coronary saphenous vein graft. Catheter Cardiovasc Interv. 2006;67:38-40. (Pubitemid 43062606)
19. Fusazaki T, Itoh T, Koeda T, Kimura T, Ogino Y, Matsui H, Sugawara S, Nakamura M. Angioscopy and OCT in Repeated In-Stent Restenosis in Saphenous Vein Graft. JACC Cardiovasc Imaging. 2010;3:785-6.20.
20. Klima T, Beard EF, Milam JD, Reul GJ, Jr., Cooley DA. Atherosclerosis of Aortocoronary Artery Saphenous Vein Bypass Grafts. Cardiovasc Dis. 1979;6:318-23. (Pubitemid 10239882)
21. Ribichini F, Pugno F, Ferrero V, Wijns W, Vacca G, Vassanelli C, Virmani R. Long-term histologic and immunohistochemic findings in human venous aorto-coronary bypass grafts. Clin Sci (Lond). 2008;114:211-20. (Pubitemid 351293996)
22. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, Montorfano M, Michev I, Airoldi F, Carlino M, Corvaja N, Colombo A. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol. 2005;45:989-94. (Pubitemid 40432427)
23. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S, Makkar RR. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv. 2005;66:507-11. (Pubitemid 41779016)
24. Hoffmann R, Pohl T, Koster R, Blindt R, Boeckstegers P, Heitzer T. Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. Heart. 2007;93:331-4. (Pubitemid 46579523)
25. Wohrle J, Nusser T, Kestler HA, Kochs M, Hombach V. Comparison of the slow-release polymerbased paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol. 2007;96:70-6. (Pubitemid 46233208)
26. Guo JC, Xu M, Wang GZ, Ma CS. Late lumen loss of drug eluting stents versus bare mental stents for saphenous vein graft intervention. Journal of Clinical Rehabilitative Tissue Engineering Research. 2008;12:6971-5.
27. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol. 2006;48: 2423-31. (Pubitemid 44895571)
28. Agostoni P, Vermeersch P, Semeraro O, Verheye S, Van Langenhove G, Van den Heuvel P, Convens C, Van den Branden F, Bruining N. Intravascular ultrasound comparison of sirolimus-eluting stent versus bare metal stent implantation in diseased saphenous vein grafts (from the RRISC [Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent] trial). Am J Cardiol. 2007;100:52-8. (Pubitemid 46970699)
29. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol. 2007;50:261-7. (Pubitemid 47039289)
30. Hong YJ, Pichard AD, Mintz GS, Kim SW, Lee SY, Kim SY, Ahn Y, Jeong MH, Satler LF, Kent KM, Suddath WO, Weissman JK, Kang JC, Waksman R. Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions. Am J Cardiol. 2010;105:179-85.
31. Rodes-Cabau J, Bertrand OF, Larose E, Dery J, Rinfret S, Bagur R, Proulx G, Nguyen CM, Cote M, Landcop M, Boudreault J, Rouleau J, Roy L, Gleeton O, Barbeau G, Noel B, Courtis J, Dagenais GR, Despres J, DeLarochelliere R. Comparison of Plaque Sealing With Paclitaxel-Eluting Stents Versus Medical Therapy for the Treatment of Moderate Nonsignificant Saphenous Vein Graft Lesions. The Moderate VEin Graft LEsion Stenting With the Taxus Stent and Intravascular Ultrasound (VELETI) Pilot Trial. Circulation. 2009;120:1978-86.
32. Brilakis ES, Lasala JM, Cox DA, Berger PB, Bowman TS, Starzyk, RM, Dawkins KD. Outcomes After Implantation of the TAXUS Paclitaxel-Eluting Stent in Saphenous Vein Graft Lesions: Results From the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) Program. JACC Cardiovasc Interv. 2010;3:742-50.
33. Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schomig A, Kastrati A. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet 2011;378:1071-8.